Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients' living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as C-11-PIB, C-11-MP4A, F-18-AV-45, and F-18-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.

Compounds for Imaging Amyloid-Β Deposits in an Alzheimer’s Brain: a Patent Review

Past And Recent Progress Of Molecular Imaging Probes For Beta-Amyloid Plaques In The Brain

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Fluorescent Imaging of Amyloid-β Deposits in Brain: An Overview of Probe Development and a Highlight of the Applications for in vivo Imaging.

Early Diagnosis of Alzheimer's Disease-Imaging of β-amyloid (A β )Plaques in the Brain with Positron Emission Tomography

Aβ-Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of Β-Amyloid Deposits

Near-infrared Fluorescent Probes for Imaging of Amyloid Plaques in Alzheimer׳s Disease.

Brain imaging in the study of Alzheimer's disease

Radiolabeled Bioactive Benzoheterocycles for Imaging Beta-Amyloid Plaques in Alzheimer'S Disease

Recent Research Progress in Fluorescent Probes for Detection of Amyloid- In Vivo

Amyloid-β Deposits Target Efficient Near-Infrared Fluorescent Probes: Synthesis, in Vitro Evaluation and in Vivo Imaging.

Targeting Β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes.

The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Benzothiazolium Derivative-Capped Silica Nanocomposites for β-Amyloid Imaging In Vivo

Progress of Near-Infrared Fluorescent Probes for beta-Amyloid Plaques in the Brain

Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents

Development of Dual Functional SPECT/fluorescent Probes for Imaging Cerebral Β-Amyloid Plaques

Shedding Light on Alzheimer's Disease: Recent Advances in Highly Selective Fluorescent Probes